Brief: Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk

COSCIENS Biopharma

29/08/2022 13:07

Aug 29 (Reuters) - Aeterna Zentaris Inc  AEZS.TO :
    * AETERNA ZENTARIS SET TO REGAIN FULL RIGHTS TO MACRILEN™
(MACIMORELIN) IN U.S. AND CANADA FROM NOVO NORDISK
    * AETERNA ZENTARIS INC - NOVO NORDISK EXERCISED RIGHT TO
TERMINATE
LICENSE AGREEMENT FOR MACRILEN
    * AETERNA ZENTARIS - NOVO NORDISK TO RETURN REGULATORY
APPROVALS,
INTELLECTUAL PROPERTY AND PROVIDE SOME OTHER ASSISTANCE FOR
TRANSITION OF MACRILEN RIGHTS
    * AETERNA ZENTARIS INC - UNTIL END OF 270-DAY PERIOD,
COMMERCIAL
LICENSE REQUIRES NOVO NORDISK TO CONTINUE SELLING AND PROMOTING
MACRILEN IN U.S.
    * AETERNA ZENTARIS INC - PLANS TO ENGAGE IN ROBUST BUSINESS
DEVELOPMENT EFFORTS TO IDENTIFY AND SECURE A NEW DEVELOPMENT AND
COMMERCIALIZATION PARTNER

Source text for Eikon:  ID:nGNX5jFRH6 
Further company coverage:  AEZS.TO 

 ((Reuters.Briefs@thomsonreuters.com;;))